594 related articles for article (PubMed ID: 23419783)
41. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
42. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
Johnson JA; Majumdar SR; Simpson SH; Toth EL
Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
[TBL] [Abstract][Full Text] [Related]
43. Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Zhao H; Liu Z; Zhuo L; Shen P; Lin H; Sun Y; Zhan S
Front Endocrinol (Lausanne); 2022; 13():874344. PubMed ID: 35846337
[TBL] [Abstract][Full Text] [Related]
44. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis.
Soranna D; Scotti L; Zambon A; Bosetti C; Grassi G; Catapano A; La Vecchia C; Mancia G; Corrao G
Oncologist; 2012; 17(6):813-22. PubMed ID: 22643536
[TBL] [Abstract][Full Text] [Related]
45. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis.
Nie Z; Zhu H; Gu M
Pharm Biol; 2016 Nov; 54(11):2636-2642. PubMed ID: 27159666
[TBL] [Abstract][Full Text] [Related]
46. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
[TBL] [Abstract][Full Text] [Related]
47. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
[TBL] [Abstract][Full Text] [Related]
48. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
49. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.
Monami M; Colombi C; Balzi D; Dicembrini I; Giannini S; Melani C; Vitale V; Romano D; Barchielli A; Marchionni N; Rotella CM; Mannucci E
Diabetes Care; 2011 Jan; 34(1):129-31. PubMed ID: 20980415
[TBL] [Abstract][Full Text] [Related]
50. Association between metformin use and risk of prostate cancer and its grade.
Margel D; Urbach D; Lipscombe LL; Bell CM; Kulkarni G; Austin PC; Fleshner N
J Natl Cancer Inst; 2013 Aug; 105(15):1123-31. PubMed ID: 23853056
[TBL] [Abstract][Full Text] [Related]
51. [Diabetes and cancer risk: oncologic considerations].
Rosta A
Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
[TBL] [Abstract][Full Text] [Related]
52. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
Azoulay L; Suissa S
Diabetes Care; 2017 May; 40(5):706-714. PubMed ID: 28428321
[TBL] [Abstract][Full Text] [Related]
53. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
Alemayehu B; Liu J; Rajpathak S; Engel SS
J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
[TBL] [Abstract][Full Text] [Related]
54. Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study.
Claesen M; Gillard P; De Smet F; Callens M; De Moor B; Mathieu C
J Clin Endocrinol Metab; 2016 Feb; 101(2):461-9. PubMed ID: 26678656
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
56. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Evans JM; Ogston SA; Emslie-Smith A; Morris AD
Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
[TBL] [Abstract][Full Text] [Related]
57. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
58. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
[TBL] [Abstract][Full Text] [Related]
59. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.
Li Y; Hu Y; Ley SH; Rajpathak S; Hu FB
Diabetes Care; 2014 Nov; 37(11):3106-13. PubMed ID: 25150157
[TBL] [Abstract][Full Text] [Related]
60. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
